REG - Destiny Pharma PLC - Efficacy of XF-70 in Fungal Skin Infections

Destiny PharmaAnnouncement

18/06/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240618:nRSR7809Sa&default-theme=true

RNS Number : 7809S  Destiny Pharma PLC  18 June 2024

Destiny Pharma plc
("Destiny Pharma" or "the Company")

 

Efficacy of XF-70 Demonstrated: A Potential New Agent for the Treatment of
Fungal Skin Infections

 

Brighton, United Kingdom - 18 June 2024 - Destiny Pharma (AIM: DEST), a
clinical stage biotechnology company focused on the development and
commercialisation of novel medicines to prevent and cure life threatening
infections, today announced new data on one of its XF Drug Platform compounds,
XF-70, which has demonstrated potency in an in vivo model of ringworm, a
common fungal skin infection, which affects up to one in four people
worldwide.

 

Ringworm is caused by a class of fungi called dermatophytes and are the
causative agents of topical fungal infections. XF-70 is a member of a novel
class of antimicrobial drugs (the XF Drug Platform) that have been shown to
have a rapid bactericidal activity even within biofilms, and is structurally
related to the company's leading drug, XF-73 which is being developed for the
prevention of post-surgical staphylococcal infections ( a clinical Phase 3
ready asset).

 

·    When applied to the skin in the ringworm model XF-70 demonstrated a
highly significant anti-fungal efficacy, (p = <0.0001) compared to
untreated control.

·    XF-70 recorded an anti-fungal efficacy of 94.9% at the highest
concentration tested.

·    Histopathological examination demonstrated fungi in the skin sections
obtained from untreated skin, but not in skin sections obtained from any of
the XF-70 treatment groups.

 

This data has been accepted as a presentation at the forthcoming Irish Fungal
Society meeting at Queen's University Belfast 19-20 June 2024.

 

As reported by Future Market Insights in January 2023 "The global ringworm
treatment market is expected to reach US$ 8.38 Billion in 2023 and is
projected to exhibit a CAGR of 5.2% from 2023 to 2033. The high prevalence of
skin diseases and the high incidence of ringworm are the major factors driving
the global market for ringworm treatments".  1 

 

Destiny Pharma plans to extend its research into anti-fungal medicine
development to identify additional market opportunities where there is
significant unmet clinical need and resistance to existing drug products.

 

Chris Tovey, Chief Executive Officer of Destiny Pharma, said: "This XF-70 data
presents an exciting opportunity for Destiny Pharma to address a growing
patient need, while demonstrating the expanded utility of the XF Drug Platform
to deliver novel antimicrobial drugs which can be used to treat both bacterial
and fungal infections. The positive in vivo data and its acceptance at the
Irish Fungal Society meeting is further validation of Destiny's XF Drug
Platform and its pivotal role in the battle against antimicrobial resistance."

 

Dr Bill Love, Chief Scientific Officer of Destiny Pharma added: "We reported
last year significant findings of anti-fungal activity of drugs from the XF
Platform and we are encouraged that XF-70's in vitro potency has translated
into an in vivo fungal infection. Fungal resistance to anti-fungal drugs is
less well known than antibiotic resistance, however it is of global concern
and the development of novel anti-fungal drugs is equally important in
addressing the impact of antimicrobial resistance."

 

 

For further information, please contact:

 

Destiny Pharma plc
Chris Tovey, CEO

Shaun Claydon, CFO

+44 (0)1273 704 440

pressoffice@destinypharma.com (mailto:pressoffice@destinypharma.com)

 

FTI Consulting

Ben Atwell / Simon Conway

+44 (0) 203 727 1000

destinypharma@fticonsulting.com (mailto:destinypharma@fticonsulting.com)

 

Shore Capital (Nominated Adviser and Broker)

Daniel Bush / James Thomas / Lucy Bowden

+44 (0) 207 408 4090

 

About Destiny Pharma

Destiny Pharma is an innovative, clinical-stage biotechnology company focused
on the development and commercialisation of novel medicines that can prevent
life-threatening infections. The Company's drug development pipeline includes
two late-stage assets XF-73 Nasal gel, a proprietary drug targeting the
prevention of post-surgical staphylococcal hospital infections including MRSA
and NTCD-M3, a microbiome-based biotherapeutic for the prevention of C.
difficile infection (CDI) recurrence which is the leading cause of hospital
acquired infection in the US.

 

For further information on the company, please visit www.destinypharma.com
(https://url.avanan.click/v2/___http:/www.destinypharma.com___.YXAxZTpzaG9yZWNhcDphOm86YTgzNTY4M2FkNmQyNzcyNmJlNWViN2U1MzU0ZjJmN2U6NjoxYWQ4OmYzMjJhZGVkMjlkZTUxYjRlYTI3M2QxNTNjYzkyYmEzZGU0ZGNlMWEzN2E2NjE3YzA5NGFkOTRkZmRjZGUyYjc6cDpG)
.

 

Forward looking statements

Certain information contained in this announcement, including any information
as to the company's strategy, plans or future financial or operating
performance, constitutes "forward-looking statements". These forward looking
statements may be identified by the use of forward-looking terminology,
including the terms "believes", "estimates", "anticipates", "projects",
"expects", "intends", "aims", "plans", "predicts", "may", "will", "seeks"
"could" "targets" "assumes" "positioned" or "should" or, in each case, their
negative or other variations or comparable terminology, or by discussions of
strategy, plans, objectives, goals, future events or intentions. These
forward-looking statements include all matters that are not historical facts.
They appear in a number of places throughout this announcement and include
statements regarding the intentions, beliefs or current expectations of the
Directors concerning, among other things, the company's results of operations,
financial condition, prospects, growth, strategies and the industries in which
the company operates. The Directors of the company believe that the
expectations reflected in these statements are reasonable but may be affected
by a number of variables which could cause actual results or trends to differ
materially. Each forward-looking statement speaks only as of the date of the
particular statement. By their nature, forward-looking statements involve
risks and uncertainties because they relate to events and depend on
circumstances that may or may not occur in the future or are beyond the
company's control. Forward looking statements are not guarantees of future
performance. Even if the company's actual results of operations, financial
condition and the development of the industries in which the company operates
are consistent with the forward-looking statements contained in this document,
those results or developments may not be indicative of results or developments
in subsequent periods.

 1  Future Markets Insights, 2023
https://www.futuremarketinsights.com/reports/ringworm-treatment-market
(https://url.avanan.click/v2/___https:/www.futuremarketinsights.com/reports/ringworm-treatment-market___.YXAxZTpzaG9yZWNhcDphOm86ZmFhZTUyNGQ0ODA3NTE1YmFkOGQxNjg5ZDMyYmY2NTU6NjowZGYzOjE2MzFmYjhiZGJhZjYwMzZlNWMzN2ZjYTQyZWZiOTk5MDc1NjkyOTczYzhhNDg1OGU2MDczZjRiZWI2Y2U0ODI6cDpG)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUBSKRSVUNAAR